|Table of Contents|

Research progress of dihydroartemisinin against gastrointestinal malignant tumors and its mechanism of action

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 04
Page:
737-743
Research Field:
Publishing date:

Info

Title:
Research progress of dihydroartemisinin against gastrointestinal malignant tumors and its mechanism of action
Author(s):
LUO Likang1; WANG Yifeng1; CHEN Yunyang1; LI Chunyan2; YANG Xiaojun1; 2; 3; 4; 5
Keywords:
dihydroartemisinin; digestive tract tumors; anti-tumor effect; review
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2024.04.027
Abstract:
China has a higher prevalence of gastrointestinal tumors.Although there have been significant advancements in tumor screening,diagnosis,and treatment in the past decade,chemotherapy remains the primary treatment for advanced cancers.However,multiple drug resistance and severe adverse effects often result in a poor prognosis for most advanced patients.A promising clinical strategy involves combining natural molecular products with anticancer drugs to enhance their anti-tumor effects.Dihydroartemisinin (DHA),the main active metabolite of artemisinin,exhibits potent antimalarial activity and antitumor effects.Its antitumor mechanism primarily involves accelerating Fe2+-mediated oxidative cell damage,inducing apoptosis in tumor cells,arresting the cell cycle,inhibiting tumor angiogenesis,and reversing multidrug resistance in tumor cells.This paper focuses on reviewing the anti-tumor effects of DHA in the digestive tract and exploring the underlying molecular mechanisms.

References:

［1］ GONZALEZ RS,RAZA A,PROPST R,et al.Recent advances in digestive tract tumors:updates from the 5th edition of the world health organization "blue book" ［J］.Arch Pathol Lab Med,2021,145(5):607-626.
［2］ QIU H,CAO S,XU R.Cancer incidence,mortality,and burden in China:a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 ［J］.Cancer Commun (Lond),2021,41(10):1037-1048.
［3］ Erratum:Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA Cancer J Clin,2020,70(4):313.
［4］ ZHU L,CHEN X,ZHU Y,et al.Dihydroartemisinin inhibits the proliferation of esophageal squamous cell carcinoma partially by targeting AKT1 and p70S6K ［J］.Front Pharmacol,2020,11:587470.
［5］ LI Q,MA Q,XU L,et al.Human telomerase reverse transcriptase as a therapeutic target of dihydroartemisinin for esophageal squamous cancer ［J］.Front Pharmacol,2021,12:769787.
［6］ JIANG M,WU Y,QI L,et al.Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma ［J］.Chem Biol Interact,2021,350:109704.
［7］ LI S,HUANG P,GAN J,et al.Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2 ［J］.Eur J Pharmacol,2019,854:232-239.
［8］ MA Q,LIAO H,XU L,et al.Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin ［J］.Chin Med,2020,15:37.
［9］ SMYTH EC,NILSSON M,GRABSCH HI,et al.Gastric cancer ［J］.Lancet,2020,396(10251):635-648.
［10］ SU T,LI F,GUAN J,et al.Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling ［J］.Phytomedicine,2019,63:152968.
［11］ YU J,GUO Z,YAN J,et al.Gastric acid-responsive ROS nanogenerators for effective treatment of helicobacter pylori infection without disrupting homeostasis of intestinal flora ［J］.Adv Sci (Weinh),2023:e2206957.
［12］ MA Y,ZHANG P,ZHANG Q,et al.Dihydroartemisinin suppresses proliferation,migration,the Wnt/β-catenin pathway and EMT via TNKS in gastric cancer ［J］.Oncol Lett,2021,22(4):688.
［13］ ZHANG S,FENG R,YUAN F,et al.The therapeutic effects of dihydroartemisinin on cisplatin-resistant gastric cancer cells ［J］.Curr Pharm Biotechnol,2022,23(2):276-286.
［14］ OZAKYOL A.Global epidemiology of hepatocellular carcinoma (HCC epidemiology) ［J］.J Gastrointest Cancer,2017,48(3):238-240.
［15］ ZHANG CZ,ZHANG H,YUN J,et al.Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo ［J］.Biochem Pharmacol,2012,83(9):1278-1289.
［16］ RUAN ML,LIU Y,ZHANG C,et al.Dihydroartemisinin engages liver fatty acid binding protein and suppresses metastatic hepatocellular carcinoma growth ［J］.Chem Commun (Camb),2023,59(19):2747-2750.
［17］ HAO L,GUO Y,PENG Q,et al.Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma ［J］.Phytomedicine,2022,96:153913.
［18］ GUO Y,PENG Q,HAO L,et al.Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma ［J］.Faseb J,2022,36(6):e22361.
［19］ HUANG TE,DENG YN,HSU JL,et al.Evaluation of the anticancer activity of a bile acid-dihydroartemisinin hybrid ursodeoxycholic-dihydroartemisinin in hepatocellular carcinoma cells ［J］.Front Pharmacol,2020,11:599067.
［20］ ZHANG H,ZHUO Y,LI D,et al.Dihydroartemisinin inhibits the growth of pancreatic cells by inducing ferroptosis and activating antitumor immunity ［J］.Eur J Pharmacol,2022,926:175028.
［21］ WANG SJ,GAO Y,CHEN H,et al.Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo ［J］.Cancer Lett,2010,293(1):99-108.
［22］ DU J,WANG X,LI Y,et al.DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism ［J］.Cell Death Dis,2021,12(7):705.
［23］ BAI B,WU F,YING K,et al.Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer ［J］.Theranostics,2021,11(13):6225-6239.
［24］ WANG Y,YANG Z,ZHU W,et al.Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling ［J］.Drug Dev Res,2023.
［25］ YU Y,CHEN D,WU T,et al.Dihydroartemisinin enhances the anti-tumor activity of oxaliplatin in colorectal cancer cells by altering PRDX2-reactive oxygen species-mediated multiple signaling pathways ［J］.Phytomedicine,2022,98:153932.
［26］ PHUNG CD,LE TG,NGUYEN VH,et al.PEGylated-paclitaxel and dihydroartemisinin nanoparticles for simultaneously delivering paclitaxel and dihydroartemisinin to colorectal cancer ［J］.Pharm Res,2020,37(7):129.
［27］ SONG X,HU Y,LI Y,et al.Overview of current targeted therapy in gallbladder cancer ［J］.Signal Transduct Target Ther,2020,5(1):230.
［28］ LUCIBELLO M,ADANTI S,ANTELMI E,et al.Phospho-TCTP as a therapeutic target of dihydroartemisinin for aggressive breast cancer cells ［J］.Oncotarget,2015,6(7):5275-5291.
［29］ ZHANG F,MA Q,XU Z,et al.Correction to:Dihydroartemisinin inhibits TCTP dependent metastasis in gallbladder cancer ［J］.J Exp Clin Cancer Res,2022,41(1):124.
［30］ THONGCHOT S,VIDONI C,FERRARESI A,et al.Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway ［J］.Mol Carcinog,2018,57(12):1735-1750.
［31］ SU Y,ZHAO D,JIN C,et al.Dihydroartemisinin induces ferroptosis in HCC by promoting the formation of PEBP1/15-LO ［J］.Oxid Med Cell Longev,2021,2021:3456725.
［32］ ZHANG Z,WANG X,WANG Z,et al.Dihydroartemisinin alleviates hepatic fibrosis through inducing ferroptosis in hepatic stellate cells ［J］.Biofactors,2021,47(5):801-818.
［33］ WANG Z,LI M,LIU Y,et al.Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response-induced upregulation of CHAC1 expression ［J］.Oncol Rep,2021,46(5):1-14.
［34］ CHEN Y,MI Y,ZHANG X,et al.Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells ［J］.J Exp Clin Cancer Res,2019,38(1):402.
［35］ MAO H,GU H,QU X,et al.Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro ［J］.Int J Mol Med,2013,31(1):213-218.
［36］ ZHOU X,ZIJLSTRA SN,SOTO-GAMEZ A,et al.Artemisinin derivatives stimulate DR5-specific TRAIL-induced apoptosis by regulating wildtype p53 ［J］.Cancers (Basel),2020,12(9):2514.
［37］ ZHOU X,SOTO-GAMEZ A,NIJDAM F,et al.Dihydroartemisinin-transferrin adducts enhance TRAIL-induced apoptosis in triple-negative breast cancer in a p53-independent and ROS-dependent manner ［J］.Front Oncol,2021,11:789336.
［38］ ELHASSANNY AEM,SOLIMAN E,MARIE M,et al.Heme-dependent ER stress apoptosis:A mechanism for the selective toxicity of the dihydroartemisinin,NSC735847,in colorectal cancer cells ［J］.Front Oncol,2020,10:965.
［39］ HAN N,YANG ZY,XIE ZX,et al.Dihydroartemisinin elicits immunogenic death through ferroptosis-triggered ER stress and DNA damage for lung cancer immunotherapy ［J］.Phytomedicine,2023,112:154682.
［40］ FU F,WANG W,WU L,et al.Inhalable biomineralized liposomes for Cyclic Ca(2+)-Burst-Centered endoplasmic reticulum stress enhanced lung cancer ferroptosis therapy ［J］.ACS Nano,2023,17(6):5486-5502.
［41］ JIANG M,WU Y,QI L,et al.Corrigendum to "Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma" Chem.Biol.Interact.350 (2021) 109704［J］.Chem Biol Interact,2022,352:109765.
［42］ LIN J.Comments on "Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells." ［J］.Chem Biol Interact,2021,345:109551.
［43］ FAN HN,ZHU MY,PENG SQ,et al.Dihydroartemisinin inhibits the growth and invasion of gastric cancer cells by regulating cyclin D1-CDK4-Rb signaling ［J］.Pathol Res Pract,2020,216(2):152795.
［44］ YI YC,LIANG R,CHEN XY,et al.Dihydroartemisinin suppresses the tumorigenesis and cycle progression of colorectal cancer by targeting CDK1/CCNB1/PLK1 signaling ［J］.Front Oncol,2021,11:768879.
［45］ ZHANG J,LI Y,WANG JG,et al.Dihydroartemisinin affects STAT3/DDA1 signaling pathway and reverses breast cancer resistance to cisplatin ［J］.Am J Chin Med,2023,51(2):445-459.
［46］ LI B,BU S,SUN J,et al.Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest ［J］.Acta Biochim Biophys Sin (Shanghai),2018,50(12):1227-1235.
［47］ ZOU J,MA Q,SUN R,et al.Dihydroartemisinin inhibits HepG2.2.15 proliferation by inducing cellular senescence and autophagy ［J］.BMB Rep,2019,52(8):520-524.
［48］ WANG L,LI J,SHI X,et al.Antimalarial dihydroartemisinin triggers autophagy within HeLa cells of human cervical cancer through Bcl-2 phosphorylation at Ser70 ［J］.Phytomedicine,2019,52:147-156.
［49］ DU J,WANG T,LI Y,et al.DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin ［J］.Free Radic Biol Med,2019,131:356-369.
［50］ GAO P,WANG LL,LIU J,et al.Dihydroartemisinin inhibits endothelial cell tube formation by suppression of the STAT3 signaling pathway ［J］.Life Sci,2020,242:117221.
［51］ LUO Q,ZHANG S,ZHANG D,et al.Effects and mechanisms of anlotinib and dihydroartemisinin combination therapy in ameliorating malignant biological behavior of gastric cancer cells ［J］.Curr Pharm Biotechnol,2021,22(4):523-533.
［52］ WANG Y,LI Z,TENG M,et al.Dihydroartemisinin inhibits activation of the AIM2 inflammasome pathway and NF-κB/HIF-1α/VEGF pathway by inducing autophagy in A431 human cutaneous squamous cell carcinoma cells ［J］.Int J Med Sci,2021,18(12):2705-2715.
［53］ DING X,ZHANG Y,LIANG J,et al.Dihydroartemisinin potentiates VEGFR-TKIs antitumorigenic effect on osteosarcoma by regulating Loxl2/VEGFA expression and lipid metabolism pathway ［J］.J Cancer,2023,14(5):809-820.
［54］ SHI S,GONG Y,HU H,et al.Topical dihydroartemisinin improves wound healing in diabetic mice ［J］.J Plast Surg Hand Surg,2023,58:26-32.
［55］ ZHANG Q,JIN L,JIN Q,et al.Inhibitory effect of dihydroartemisinin on the proliferation and migration of melanoma cells and experimental lung metastasis from melanoma in mice ［J］.Front Pharmacol,2021,12:727275.
［56］ CAI X,MIAO J,SUN R,et al.Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer ［J］.Pharmacol Res,2021,170:105701.
［57］ GAO J,MA F,WANG X,et al.Combination of dihydroartemisinin and resveratrol effectively inhibits cancer cell migration via regulation of the DLC1/TCTP/Cdc42 pathway ［J］.Food Funct,2020,11(11):9573-9584.
［58］ D’AMICO S,KRASNOWSKA EK,MANNI I,et al.DHA affects microtubule dynamics through reduction of phospho-TCTP levels and enhances the antiproliferative effect of T-DM1 in trastuzumab-resistant HER2-positive breast cancer cell lines ［J］.Cells,2020,9(5):1260.

Memo

Memo:
国家卫健委胃肠肿瘤诊治重点实验室2022年度硕博士/博士后基金项目(编号：NHCDP2022001);甘肃省省级科技计划重点研发项目(编号：21YF5WA027);甘肃省创新基地和人才项目资助(编号：20JR10RA433);甘肃省卫生健康行业科研计划(编号：GSWSKY2020-45);甘肃省人民医院博士研究生导师培育项目(编号：22GSSYA-3)
Last Update: 1900-01-01